Moving Life Science Innovations along the path
From Discovery To Development To Delivery
OUR VISION OF THE FUTURE: Arizona is a top-ten life science state.
OUR MISSION: AZBio supports the needs of Arizona’s growing life science ecosystem.
Arizona’s bioscience industry is growing rapidly and reached more than 36,000 jobs spanning 2,912 business establishments in 2021. Industry employment has grown by nearly 22 percent since 2018—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona’s universities conducted $602 million in R&D activities in bioscience-related fields in 2020, fueled in part by steadily increasing NIH awards to Arizona institutions since 2018. Venture capital investments in Arizona bioscience companies increased significantly in 2021, and during the 2018-21 period totaled $565 million. Arizona inventors have been awarded 2,283 bioscience related patents since 2018, among the second quintile of states in patent activity. Read the Report: AZ-BIO2022 - state profile
IN THE LOOP
AZBio In The Loop is your opportunity to stay up to date on what is happening across Arizona's Life Science and Healthcare Community.
SubscribeAZBio Members Are Making LIFE Better
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on growing Arizona’s bioscience industry.
AZBio Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector. As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.
AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations.
Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.
Success Stories – Good News from Arizona’s BioIndustry
Jennifer Kehlet Barton embarks on tenure as president of SPIE, bolstering University of Arizona’s global impact
As the BIO5 Institute director assumes her presidency of SPIE, the international society for optics and photonics in 2024, she propels the international society for optics and photonics into new frontiers and underscores her role as a leader in cutting-edge research and innovation while representing UArizona.
Ranking Member Cassidy Seeks Information from Stakeholders on Regulation of Clinical Tests
WASHINGTON – Today, U.S. Senator Bill Cassidy, M.D. (R-LA), ranking member of the Senate Health, Education, Labor, and Pensions (HELP) Committee, requested information from stakeholders on ways to improve regulation of clinical tests in the United States.
Chairs Rodgers and Guthrie Announce Health Subcommittee Hearing on Regulation of Diagnostic Tests
The Energy and Commerce Health Subcommittee will hold a hearing, “Evaluating Approaches to Diagnostic Test Regulation and the Impact of FDA’s Proposed Rule” on Thursday, March 21 at 10:00 AM EDT. The E&C hearing will be live streamed starting at 7 AM AZ/PDT via https://energycommerce.house.gov/
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
PRINCETON, N.J.–Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received […]
Events
- MDMA Annual Conference
        Apr 17, 2024 - Washington - Arizona’s Bioscience Roadmap Update
        Apr 22, 2024 - - AZBioPEERS: In-State Incubators, Exploring Local Resources
        Apr 23, 2024 - - Tucson Symposium 2024
        Apr 23, 2024 - Tucson - Ginny L. Clements Breast Cancer Research Institute Annual Symposium
        Apr 24, 2024 - TUCSON